Clinical Trial Update: S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that the phase 1/2 study of S095033 in combination with paclitaxel for advanced or metastatic esophageal squamous cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• S095033

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN